Sai Parenterals reports strong FY26 Growth Driven by CDMO Exports, Noumed Integration
Hyderabad, May 23 (TNT):Sai Parenterals Limited on Saturday reported robust financial performance for the quarter and financial year ended March 31, 2026, driven by strong CDMO exports and integration of Australia-based Noumed Pharmaceuticals.
In a statement, the company said its consolidated Q4 FY26 revenue stood at ₹197.93 crore, registering growth of 166.65 per cent, while EBITDA rose 366.97 per cent to ₹28.97 crore. Profit After Tax surged 736.04 per cent to ₹13.25 crore during the quarter.
For the full financial year FY26, consolidated revenue stood at ₹380.99 crore, reflecting 140.37 per cent growth, while EBITDA increased 33.29 per cent to ₹47.21 crore and PAT rose 45.52 per cent to ₹14.37 crore.
The company stated that standalone FY26 revenue stood at ₹164.99 crore with 30.65 per cent year-on-year growth, driven by deeper engagement with export market customers.
Sai Parenterals highlighted its acquisition of a 74.6 per cent controlling stake in Australia-based Noumed Pharmaceuticals Pty Limited in November 2025, stating that the acquisition provides access to 451 product dossiers and strengthens its presence in the Australian pharmaceutical market.
The company also noted that a state-of-the-art pharmaceutical manufacturing facility is under development in Adelaide, Australia, as part of its strategy to build a vertically integrated pharmaceutical platform by FY28.
According to the company, 88 product dossiers were added across regulated and emerging markets during FY26, while 67 additional dossiers are expected to be commercialised in FY27.
Sai Parenterals further stated that it successfully completed its IPO in March 2026, raising ₹285 crore.
The company plans to utilise ₹130 crore towards capacity expansion, manufacturing upgrades and establishment of a dedicated R&D centre in India.
Managing Director Anil KK said the company’s profitability and operational scale had improved significantly and expressed confidence in sustained growth momentum in FY27 and beyond.
TNT TS
